Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Indi Molecular logo — Indi Molecular is an emerging life sciences company developi...

Indi Molecular

Indi Molecular is an emerging life sciences company developing synthetic molecules with antibody-like properties.

Founded 2013 United States Culver City, United States 2 employees Series A Total: $11.50M Biotechnology, Health Care

General Information

Company Name Indi Molecular
Founded Year 2013
Location United States Culver City, United States
Employees 2
Industries Biotechnology, Health Care
Funding Stage Series A
Business Model B2B, Platform
Revenue Model Licensing, Product Sales, Value Based Pricing
Social

BounceWatch is an independent company data service, not affiliated with Indi Molecular. To contact Indi Molecular, visit indimolecular.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Indi Molecular compare?

A PDF of Indi Molecular and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Indi Molecular soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Indi Molecular

Indi Molecular is an emerging force in the Biotechnology and Health Care sectors, focusing on the development of synthetic molecules that mimic antibody properties. With a strategy centered around its unique protein catalyzed capture (PCC) technology, the company aims to revolutionize therapeutic and diagnostic processes. PCCs serve dual purposes as precision in vivo PET diagnostics and targeted therapeutics, notably in radiotherapy and chemotherapy.

Founded in 2013, Indi Molecular secured initial financial momentum with a $1.8 million seed round, subsequently followed by a substantial $11.5 million Series A in 2017. This investment round was backed by prominent investors including Asset Management Ventures, M Ventures, Legend Capital, and SABEY. Headquartered in the United States, the company is strategically positioned to address critical gaps in current therapeutic methodologies with its innovative PCC technology.

Business keywords: Life Sciences, Therapeutics, Synthetic Molecules, Protein Catalyzed Capture, Antibody-like Properties, Precision Medicine, PET Diagnostic, Radiotherapy, Chemotherapy, Start-up, Series A Funding, Seed Round, Innovation, Medical Technology

Services & Products

Development of small molecule oncology therapeutics
Protein Catalyzed Capture agent creation
Synthetic peptide therapeutic solutions

Target Customers

Pharmaceutical companies Biotechnology firms Cancer treatment centers Oncology researchers

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $11.50M 4
Asset Management Ventures M Ventures Legend Capital
Asset Management Ventures, M Ventures +2
01 Jun 2017
Seed Undisclosed 1
Asset Management Ventures
Asset Management Ventures
01 Oct 2013

Indi Molecular Alternatives & Competitors

View All Alternatives
Indi Molecular vs
Synbio Technologies
Synbio Technologies United States

Changing the world, one sequence at a time.

25 employees
Biotechnology, Health Care
Indi Molecular vs
Convergent RnR Ltd.
Convergent RnR Ltd. Israel

A NEW APPROACH TO ONCOLOGY RADIOTHERAPY

Venture round
18 employees
Biotechnology, Health Care
Indi Molecular vs
GRO Biosciences
GRO Biosciences United States

GRObio’s groundbreaking science expands the amino acid alphabet to deliver on the promise of protein...

Series B
32 employees
Biotechnology, Health Care
View all alternatives

FAQ About Indi Molecular

Indi Molecular is an emerging life sciences company developing synthetic molecules with antibody-like properties.
Indi Molecular was founded in 2013.
Indi Molecular is headquartered in Culver City, United States.
Indi Molecular operates in Biotechnology and Health Care. Its work centres on Life Sciences, Therapeutics, Synthetic Molecules and Protein Catalyzed Capture. Its customers include Pharmaceutical companies, Biotechnology firms and Cancer treatment centers.
Indi Molecular has a B2B and Platform business model. Its revenue comes from Licensing, Product Sales and Value Based Pricing.
Indi Molecular has approximately 2 employees.
Indi Molecular has completed 2 funding rounds, raising a total of $11.50M. The latest funding stage is Series A.
Indi Molecular offers: Development of small molecule oncology therapeutics, Protein Catalyzed Capture agent creation, Synthetic peptide therapeutic solutions.
Top alternatives and competitors to Indi Molecular include Synbio Technologies, Convergent RnR Ltd., GRO Biosciences, POP Biotechnologies, Quantum-Si. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Indi Molecular and Synbio Technologies are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Indi Molecular, https://bouncewatch.com/company/indi-molecular, updated 20 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout